AlphaTON Capital (ATON) AI Stock Analysis

• Market Cap: $11.60M
• Dividend Yield: N/A
• Average Volume (3M): 57.21K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.13
• Revenue Growth: N/A
• EPS Growth: 48.91%
• Country: US
• Employees: 4
• Sector: Healthcare
• Sector Strength: 52
• Industry: Asset Management
• EPS (TTM): N/A
• Shares Outstanding: 2,278,622
• 10 Day Avg. Volume: 72,431
• 30 Day Avg. Volume: 57,212
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 48 Neutral
• Price Target: ―

Portage Biotech Inc. exhibits significant financial weaknesses, such as no revenue and persistent losses, which heavily weigh down the overall score. Despite strong technical indicators suggesting bullish momentum, the poor valuation metrics and financial performance hinder the stock's attractiveness. The absence of earnings call data or notable corporate events leaves these factors out of consideration.

AlphaTON Capital Business Overview & Revenue Model

Company Description

Portage Biotech Inc. (PRTG) is a biotechnology company focused on developing innovative immuno-oncology therapies. The company operates primarily in the health care sector, specifically targeting the treatment of cancer through its proprietary platform technologies and a robust pipeline of novel therapeutics. Portage Biotech aims to enhance the body's immune response to fight cancer, offering potential breakthroughs in cancer treatment.

How the Company Makes Money

Portage Biotech Inc. generates revenue primarily through the development and commercialization of its proprietary cancer immunotherapy products. The company's revenue streams include licensing agreements, strategic partnerships, and collaborations with pharmaceutical companies. These partnerships often involve milestone payments, royalties on sales, and joint development efforts that leverage Portage's innovative technologies. Additionally, the company may receive funding from grants and research collaborations that support the advancement of its therapeutic pipeline. Portage's focus on cutting-edge oncology solutions positions it to capitalize on the growing demand for effective cancer treatments, contributing to its financial performance.

AlphaTON Capital Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

AlphaTON Capital Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.89
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATON, the sentiment is Negative. The current price of 5.89 is below the 20-day moving average (MA) of 7.73, below the 50-day MA of 6.83, and below the 200-day MA of 6.13, indicating a bearish trend. The MACD of -0.37 indicates Positive momentum. The RSI at 39.19 is Neutral, neither overbought nor oversold. The STOCH value of 10.57 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATON.

AlphaTON Capital Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BOLT	52 Neutral	$9.96M	―	-81.33%	―	-62.68%	23.94%
Sector *	51 Neutral	$7.95B	-0.38	-43.43%	2.22%	22.30%	-1.83%
ATON	48 Neutral	$11.60M	―		―	―	48.91%
PHIO	42 Neutral	$11.68M	―	-102.18%	―	―	85.26%
CANF	40 Underperform	$14.24M	―	-122.28%	―	―	―
CLRB	34 Underperform	$15.90M	―	-273.88%	―	―	73.37%
MTVA	33 Underperform	$16.69M	―	-129.46%	―	―	64.35%